These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 11856830)

  • 1. Structure of a Cys25-->Ser mutant of human cathepsin S.
    Turkenburg JP; Lamers MB; Brzozowski AM; Wright LM; Hubbard RE; Sturt SL; Williams DH
    Acta Crystallogr D Biol Crystallogr; 2002 Mar; 58(Pt 3):451-5. PubMed ID: 11856830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The crystal structure of human cathepsin F and its implications for the development of novel immunomodulators.
    Somoza JR; Palmer JT; Ho JD
    J Mol Biol; 2002 Sep; 322(3):559-68. PubMed ID: 12225749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structure of human procathepsin X: a cysteine protease with the proregion covalently linked to the active site cysteine.
    Sivaraman J; Nägler DK; Zhang R; Ménard R; Cygler M
    J Mol Biol; 2000 Jan; 295(4):939-51. PubMed ID: 10656802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression, purification, crystallization and preliminary X-ray diffraction studies of human cathepsin F complexed with an irreversible vinyl sulfone inhibitor.
    Ho JD; Meltser Y; Buggy JJ; Palmer JT; Elrod KC; Chan H; Mortara KD; Somoza JR
    Acta Crystallogr D Biol Crystallogr; 2002 Dec; 58(Pt 12):2187-90. PubMed ID: 12454497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystal structure of human cathepsin S.
    McGrath ME; Palmer JT; Brömme D; Somoza JR
    Protein Sci; 1998 Jun; 7(6):1294-302. PubMed ID: 9655332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The crystal structure of a Cys25 -> Ala mutant of human procathepsin S elucidates enzyme-prosequence interactions.
    Kaulmann G; Palm GJ; Schilling K; Hilgenfeld R; Wiederanders B
    Protein Sci; 2006 Nov; 15(11):2619-29. PubMed ID: 17075137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specificity determinants of human cathepsin s revealed by crystal structures of complexes.
    Pauly TA; Sulea T; Ammirati M; Sivaraman J; Danley DE; Griffor MC; Kamath AV; Wang IK; Laird ER; Seddon AP; Ménard R; Cygler M; Rath VL
    Biochemistry; 2003 Mar; 42(11):3203-13. PubMed ID: 12641451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High level expression and crystallization of recombinant human cathepsin S.
    Brömme D; McGrath ME
    Protein Sci; 1996 Apr; 5(4):789-91. PubMed ID: 8845771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide ketobenzoxazole inhibitors bound to cathepsin K.
    McGrath ME; Sprengeler PA; Hill CM; Martichonok V; Cheung H; Somoza JR; Palmer JT; Janc JW
    Biochemistry; 2003 Dec; 42(51):15018-28. PubMed ID: 14690410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced crystallization of the Cys18 to Ser mutant of bovine gammaB crystallin.
    Asherie N; Pande J; Pande A; Zarutskie JA; Lomakin J; Lomakin A; Ogun O; Stern LJ; King J; Benedek GB
    J Mol Biol; 2001 Dec; 314(4):663-9. PubMed ID: 11733987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the single cysteine residue, Cys 3, of human and bovine cystatin B (stefin B) in the inhibition of cysteine proteinases.
    Pol E; Björk I
    Protein Sci; 2001 Sep; 10(9):1729-38. PubMed ID: 11514663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
    Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ
    J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution to activity of histidine-aromatic, amide-aromatic, and aromatic-aromatic interactions in the extended catalytic site of cysteine proteinases.
    Brömme D; Bonneau PR; Purisima E; Lachance P; Hajnik S; Thomas DY; Storer AC
    Biochemistry; 1996 Apr; 35(13):3970-9. PubMed ID: 8672429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 3: heterocyclic P3.
    Tully DC; Liu H; Alper PB; Chatterjee AK; Epple R; Roberts MJ; Williams JA; Nguyen KT; Woodmansee DH; Tumanut C; Li J; Spraggon G; Chang J; Tuntland T; Harris JL; Karanewsky DS
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1975-80. PubMed ID: 16446091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of putative cathepsin S in mangrove red snapper Lutjanus argentimaculatus and its role in antigen presentation.
    Zhou J; Li L; Cai ZH
    Dev Comp Immunol; 2012 May; 37(1):28-38. PubMed ID: 22210546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An orally active reversible inhibitor of cathepsin S inhibits human trans vivo delayed-type hypersensitivity.
    Desai SN; White DM; O'shea KM; Brown ML; Cywin CL; Spero DM; Panzenbeck MJ
    Eur J Pharmacol; 2006 May; 538(1-3):168-74. PubMed ID: 16631730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition mechanism of cathepsin L-specific inhibitors based on the crystal structure of papain-CLIK148 complex.
    Tsuge H; Nishimura T; Tada Y; Asao T; Turk D; Turk V; Katunuma N
    Biochem Biophys Res Commun; 1999 Dec; 266(2):411-6. PubMed ID: 10600517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Species differences between human and rat in the substrate specificity of cathepsin K.
    Tada S; Tsutsumi K; Ishihara H; Suzuki K; Gohda K; Teno N
    J Biochem; 2008 Oct; 144(4):499-506. PubMed ID: 18664521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of papain as a model for the structure-based design of cathepsin K inhibitors: crystal structures of two papain-inhibitor complexes demonstrate binding to S'-subsites.
    LaLonde JM; Zhao B; Smith WW; Janson CA; DesJarlais RL; Tomaszek TA; Carr TJ; Thompson SK; Oh HJ; Yamashita DS; Veber DF; Abdel-Meguid SS
    J Med Chem; 1998 Nov; 41(23):4567-76. PubMed ID: 9804696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The consequences of lysosomotropism on the design of selective cathepsin K inhibitors.
    Black WC; Percival MD
    Chembiochem; 2006 Oct; 7(10):1525-35. PubMed ID: 16921579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.